The prostate cancer section is a comprehensive resource for urology news and expert insights. Read more at Urology Times.

The Novel Tracer 89Zr-TLX250 Main Discussion Topics: 89Zr-TLX250 is an antibody that binds to carbonic anhydrase IX (CAIX). CAIX is an enzyme expressed on the surface of most clear cell renal cell ...

Prostate Cancer Awareness: Not Just a Month Prostate cancer awareness isn’t just about blue ribbons in September. As I’ve often said, “Cancer doesn’t take a holiday or a weekend.” Prostate cancer ...

The treatment landscape for high-risk, BCG-unresponsive non–muscle-invasive bladder cancer has expanded significantly, with 3 FDA-approved bladder-sparing therapies now available: pembrolizumab, ...

Key Takeaways Zanzalintinib and nivolumab showed a 63% response rate and 18.5-month median PFS in stage 4 RCC. The study included patients with advanced RCC, treated with zanzalintinib plus nivolumab ...

First-line nivolumab (Opdivo) plus ipilimumab (Yervoy) continued to show improved survival and durable response benefits vs sunitinib (Sutent) in patients with previously untreated advanced renal cell ...

Key Takeaways The FDA will evaluate talazoparib and enzalutamide for mCRPC patients unselected for HRR gene alterations, expanding beyond HRR-positive cases. TALAPRO-2 trial data showed significant ...

Key Takeaways UGN-102's NDA is supported by the phase 3 ENVISION trial, showing a 79.6% complete response rate at 3 months for LG-IR-NMIBC patients. The FDA is evaluating if the observed duration of ...

Clinical Brief: Initial Presentation and Management of Metastatic Hormone-Sensitive Prostate Cancer Main Discussion Topics Patient Profile: A 69-year-old Black man presenting with fatigue, nocturnal ...

In a study presented at the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction 2025 Winter Meeting in Rancho Mirage, California, investigators presented data on the β-3 agonist ...

Key Takeaways Vibegron treatment in men with OAB and BPH showed positive long-term safety and efficacy over 52 weeks. The extension trial involved 276 participants, with 90.6% completing the study.

At this year’s American Urological Association (AUA) Annual Meeting in Las Vegas, Nevada, the AUA released their new guideline on genitourinary syndrome of menopause in collaboration with the Society ...